TP53 and B-cell chronic lymphocytic leukemia: Recent clinical trials in CLL patients demonstrated that unmutated IGHV is associated with unfavorable outcomes with conventional chemotherapy or chemoimmunotherapy regimens.7, 8, 9 Multivariate analysis established del(17p), TP53 mutation or unmutated IGHV were each important independent prognostic factors for survival.7, 9TP53 mutation without del(17p) is also of prognostic importance, with both markers demonstrating independent prognostic significance in multivariate analyses.10